Systemic and large local reactions during subcutaneous grass pollen immunotherapy in children

Allergic DiseasesImmunotherapy

Basophil Sensitivity Reflects the Long-term Clinical Outcome of Subcutaneous Immunotherapy in Grass Pollen Allergic Patients

Allergy.

Schmid JM, Würtzen PA, Siddhuraj P, Jogdand P, Petersen CG, Dahl R, Erjefält JS, Hoffmann HJ

doi: 10.1111/all.14264.

Immunotherapy

Nasal Allergen Neutralising IgG₄ Antibodies Block IgE-mediated Responses: Novel biomarker of Subcutaneous Grass Pollen Immunotherapy

J Allergy Clin Immunol.

Shamji MH, Kappen J, Abubakar-Waziri H, Zhang J, Steveling E, Watchman S, Kouser L, Eifan A, Switzer A, Varrichi G, Marone G, Couto-Francisco NC, Calderon M, Durham SR

doi: 10.1016/j.jaci.2018.09.039.

Allergic Diseases

Large local reactions to Hymenoptera stings: outcome of re-stings in real-life

Allergy.

Bilò MB, Martini M, Pravettoni V, Bignardi D, Bonadonna P, Cortellini G, Kosinska M, Macchia D, Mauro M, Meucci E, Nittner-Marszalska M, Patella V, Pio R, Quercia O, Reccardini F, Ridolo E, Rudenko M, Severino M

doi: 10.1111/all.13863.

Allergic Diseases

Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: a randomised controlled trial

J Allergy Clin Immunol Pract.

Janeczek K, Emeryk A, Rachel M, Duma D, Zimmer L, Poleszak E

doi: 10.1016/j.jaip.

Immunotherapy

Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

JAMA.

Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, Sever ML, Bahnson HT, Lawson K, Harris KM, Plough AG, Panza JL, Qin T, Lim N, Tchao NK, Togias A, Durham SR

doi: 10.1001/jama.2016.21040.

Immunotherapy

Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials

J Allergy Clin Immunol Pract.

Halken S, Roberts G, Valovirta E, Nolte H, Hulstrøm V, Blaiss MS

doi: 10.1016/j.jaip.2020.01.008.

Immunotherapy

Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen season

J Allergy Clin Immunol.

Ellis AK, Frankish CW, Armstrong K, Steacy L, Tenn MW, Pawsey S, Hafner RP

doi: 10.1016/j.jaci.2019.09.010.

Allergic Diseases

Sensitization to grass pollen allergen molecules in a birth cohort - Phl p 4 as early indicator of grass pollen allergy

J Allergy Clin Immunol.

Westman M, Åberg K, Apostolovic D, Lupinek C, Gattinger P, Mittermann I, Andersson N, Melén E, Bergström A, Antó JM, Bousquet J, Valenta R, Wickman M, van Hage M, MeDALL consortium.

doi: 10.1016/j.jaci.2020.01.006.

Allergic DiseasesImmunotherapy

Intralymphatic Immunotherapy improves grass pollen allergic rhinoconjunctivitis. A three-year randomized placebo-controlled trial

J Allergy Clin Immunol.

Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ

doi: 10.1016/j.jaci.2020.07.002.

Related content

Basophil Sensitivity Reflects the Long-term Clinical Outcome of Subcutaneous Immunotherapy in Grass Pollen Allergic Patients

Nasal Allergen Neutralising IgG4 Antibodies Block IgE-mediated Responses: Novel biomarker of Subcutaneous Grass Pollen Immunotherapy

Large local reactions to Hymenoptera stings: outcome of re-stings in real-life

Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: a randomised controlled trial

Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials

Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen season

Sensitization to grass pollen allergen molecules in a birth cohort - Phl p 4 as early indicator of grass pollen allergy

Intralymphatic Immunotherapy improves grass pollen allergic rhinoconjunctivitis. A three-year randomized placebo-controlled trial

Nasal Allergen Neutralising IgG₄ Antibodies Block IgE-mediated Responses: Novel biomarker of Subcutaneous Grass Pollen Immunotherapy